Interpretation of the essential updates in guidelines for the prevention and treatment of chronic hepatitis B (Version 2022).
10.3760/cma.j.cn501113-20230324-00127
- Author:
Hong YOU
1
;
Ya Meng SUN
1
;
Meng Yang ZHANG
1
;
Yue Min NAN
2
;
Xiao Yuan XU
3
;
Tai Sheng LI
4
;
Gui Qiang WANG
3
;
Jin Lin HOU
5
;
Zhongping DUAN
6
;
Lai WEI
7
;
Fu Sheng WANG
8
;
Ji Dong JIA
1
;
Hui ZHUANG
9
Author Information
1. Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
2. Third Hospital of Hebei Medical University, Shijiazhuang 050051, China.
3. Peking University First Hospital, Beijing 100034, China.
4. Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
5. Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
6. Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
7. Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing 102218, China.
8. The Fifth Medical Center of PLA General Hospital, Beijing 100039, China.
9. Peking University Health Science Center, Beijing 100191, China.
- Publication Type:Journal Article
- Keywords:
Chronic hepatitis B;
Guideline;
Interpretation;
Update
- MeSH:
Humans;
Hepatitis B, Chronic/drug therapy*;
Hepatitis B/drug therapy*;
Hepatitis B virus;
Antiviral Agents/therapeutic use*;
Gastroenterology
- From:
Chinese Journal of Hepatology
2023;31(4):385-388
- CountryChina
- Language:Chinese
-
Abstract:
Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association update the guidelines for the prevention and treatment of chronic hepatitis B (version 2022) in 2022. The latest guidelines recommend more extensive screening and more active antiviral treating for hepatitis B virus infection. This article interprets the essential updates in the guidelines to help deepen understanding and better guide the clinical practice.
